Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Expands By 5.9%

by · The Markets Daily

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) was the target of a significant increase in short interest in August. As of August 31st, there was short interest totalling 4,300,000 shares, an increase of 5.9% from the August 15th total of 4,060,000 shares. Approximately 21.4% of the shares of the stock are short sold. Based on an average trading volume of 267,200 shares, the days-to-cover ratio is presently 16.1 days.

Dianthus Therapeutics Stock Performance

Shares of DNTH traded up $1.88 during midday trading on Thursday, hitting $27.88. 32,325 shares of the stock were exchanged, compared to its average volume of 185,180. Dianthus Therapeutics has a 52-week low of $6.58 and a 52-week high of $33.77. The stock has a fifty day simple moving average of $28.01 and a 200 day simple moving average of $26.11. The firm has a market cap of $818.25 million, a P/E ratio of -4.76 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The firm had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. As a group, equities research analysts forecast that Dianthus Therapeutics will post -2.32 EPS for the current fiscal year.

Analyst Ratings Changes

DNTH has been the subject of a number of analyst reports. Baird R W raised shares of Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, August 12th. Cantor Fitzgerald began coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They issued an “overweight” rating on the stock. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, Wedbush decreased their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $44.71.

Get Our Latest Research Report on DNTH

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently added to or reduced their stakes in DNTH. Bain Capital Life Sciences Investors LLC acquired a new position in shares of Dianthus Therapeutics in the first quarter worth $89,761,000. RA Capital Management L.P. purchased a new stake in Dianthus Therapeutics during the 1st quarter worth about $69,990,000. Vanguard Group Inc. raised its position in Dianthus Therapeutics by 250.0% in the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after purchasing an additional 384,182 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Dianthus Therapeutics in the 1st quarter valued at about $11,251,000. Finally, Vestal Point Capital LP acquired a new position in shares of Dianthus Therapeutics during the fourth quarter worth about $1,404,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Read More